Israel - English - Ministry of Health

fischer pharmaceuticals ltd, israel - sulfacetamide sodium - eye drops, solution - sulfacetamide sodium 10 % - sulfacetamide - sulfacetamide - eye infections caused by micro-organisms sensitive to sulfacetamide.

United States - English - NLM (National Library of Medicine)

cintex services, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. the object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. these side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

United States - English - NLM (National Library of Medicine)

cintex services, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. the object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. these side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

United States - English - NLM (National Library of Medicine)

cintex services, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - each gram contains 100 mg of sodium sulfacetamide in a vehicle consisting of: benzyl alcohol, cetearyl alcohol (and) peg-3 distearoylamidoethylmonium methosulfate (and) polysorbate 60, cetyl alcohol, fragrance, glyceryl stearate (and) peg-100 stearate, lithium magnesium sodium silicate, magnesium aluminum silicate, phenoxyethanol, propylene glycol, purified water, sodium lauryl sulfate, sodium thiosulfate, stearyl alcohol and xanthan gum. sodium sulfacetamide is a sulfonamide with antibacterial activity. sodium sulfacetamide is c 8 h 9 n 2 nao 3 s·h 2 o with molecular weight of 254.24. chemically, sodium sulfacetamide is n-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. the structural formula is: sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. it is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether. this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

cintex services, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - each gram contains 100 mg of sodium sulfacetamide in a vehicle consisting of: citric acid, disodium edta, fragrance, methylparaben, peg-150 pentaerythrityl tetrastearate (and) aqua (and) peg-6 caprylic/capric glycerides, peg-60 almond glycerides, propylene glycol, propylparaben, purified water, sodium chloride, and sodium laureth sulfate (and) cocamide dea (and) cocamidopropyl betaine (and) glycol stearate. sodium sulfacetamide is a sulfonamide with antibacterial activity. sodium sulfacetamide is c 8 h 9 n 2 nao 3 s·h 2 o with molecular weight of 254.24. chemically, sodium sulfacetamide is n-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. the structural formula is: sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. it is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether. this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - prednisolone acetate sulfacetamide sodium phenylephrine hydrochloride - eye drops suspension - 0.22/10.3 %w/v

Canada - English - Health Canada

pharma stulln inc. - prednisolone acetate; sulfacetamide sodium - ointment - 5mg; 100mg - prednisolone acetate 5mg; sulfacetamide sodium 100mg - antibacterials

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 10 mg in 1 ml - klaron lotion is indicated in the topical treatment of acne vulgaris . klaron lotion is contraindicated for use by patients having known hypersensitivity to sulfonamides or any other component of this preparation (see warnings section).

United States - English - NLM (National Library of Medicine)

stratus pharamceuticals, inc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 g

United States - English - NLM (National Library of Medicine)

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.